Zorvolex is owned by Zyla.
Zorvolex contains Diclofenac.
Zorvolex has a total of 7 drug patents out of which 0 drug patents have expired.
Zorvolex was authorised for market use on 18 October, 2013.
Zorvolex is available in capsule;oral dosage forms.
Zorvolex can be used as treatment of pain.
The generics of Zorvolex are possible to be released after 23 April, 2030.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9186328 | ZYLA | Formulation of diclofenac |
Apr, 2030
(6 years from now) | |
US9180095 | ZYLA | Formulation of diclofenac |
Apr, 2030
(6 years from now) | |
US8999387 | ZYLA | Formulation of diclofenac |
Apr, 2030
(6 years from now) | |
US9173854 | ZYLA | Formulation of diclofenac |
Apr, 2030
(6 years from now) | |
US9180096 | ZYLA | Formulation of diclofenac |
Apr, 2030
(6 years from now) | |
US9017721 | ZYLA | Formulation of diclofenac |
Apr, 2030
(6 years from now) | |
US8679544 | ZYLA | Formulation of diclofenac |
Apr, 2030
(6 years from now) |
Drugs and Companies using DICLOFENAC ingredient
Market Authorisation Date: 18 October, 2013
Treatment: Treatment of pain
Dosage: CAPSULE;ORAL
13
United States
5
China
5
Korea, Republic of
4
Australia
3
Hong Kong
3
New Zealand
2
Singapore
2
Japan
2
Mexico
2
European Union
1
Philippines
1
Malaysia
1
AP
1
Denmark
1
Brazil
1
Canada
1
Ukraine
1
Morocco
1
EA
1
Israel
1
South Africa
1
Colombia
1
Tunisia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic